Author:
Lopez-Erauskin Jone,Bravo-Hernandez Mariana,Presa Maximiliano,Baughn Michael W.,Melamed Ze’ev,Beccari Melinda S.,Agra de Almeida Quadros Ana Rita,Zuberi Aamir,Ling Karen,Platoshyn Oleksandr,Niño-Jara Elkin,Ndayambaje I. Sandra,Arnold-Garcia Olatz,McAlonis-Downes Melissa,Cabrera Larissa,Artates Jonathan W.,Ryan Jennifer,Bennett Frank,Jafar-nejad Paymaan,Rigo Frank,Marsala Martin,Lutz Cathleen M.,Cleveland Don W.,Lagier-Tourenne Clotilde
Abstract
AbstractThe human mRNA most affected by TDP-43 loss-of-function is transcribed from theSTMN2gene and encodes stathmin-2 (also known as SCG10), whose loss is a neurodegenerative disease hallmark. Here using multiplein vivoapproaches, including transient antisense oligonucleotide (ASO)-mediated suppression, chronic shRNA-mediated depletion in aging mice, and germline deletion, we establish stathmin-2 to be essential for acquisition and maintenance of neurofilament-dependent structuring of axoplasm critical for maintaining diameter and conduction velocity of large-myelinated axons. Sustained stathmin-2 loss from an otherwise mature adult nervous system is demonstrated over a time course of eight months to initiate and drive motor neuron disease that includes 1) shrinkage in inter-neurofilament spacing that is required to produce a three-dimensional space filling array that defines axonal caliber, 2) collapse of mature axonal caliber with tearing of outer myelin layers, 3) reduced conduction velocity, 4) progressive motor and sensory deficits (including reduction of the pain transducing neuropeptide CGRP), and 5) muscle denervation. Demonstration that chronic stathmin-2 reduction is itself sufficient to trigger motor neuron disease reinforces restoration of stathmin-2 as an attractive therapeutic approach for TDP-43-dependent neurodegeneration, including the fatal adult motor neuron disease ALS.
Publisher
Cold Spring Harbor Laboratory